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Abstract
Background: Glucocorticoids (GC's) play an integral role in treatment strategies designed to
combat various forms of hematological malignancies. GCs also are powerful inhibitors of the
immune system, through regulation of appropriate cytokines and by causing apoptosis of immature
thymocytes. By activating the glucocorticoid receptor (GR), GCs evoke apoptosis through
transcriptional regulation of a complex, interactive gene network over a period of time preceding
activation of the apoptotic enzymes. In this study we used microarray technology to determine
whether several disparate types of hematologic cells, all sensitive to GC-evoked apoptosis, would
identify a common set of regulated genes. We compared gene expression signatures after
treatment with two potent synthetic GCs, dexamethasone (Dex) and cortivazol (CVZ) using a
panel of hematologic cells. Pediatric CD4+/CD8+ T-cell leukemia was represented by 3 CEM
clones: two sensitive, CEM-C7–14 and CEM-C1–6, and one resistant, CEM-C1–15, to Dex. CEM-
C1–15 was also tested when rendered GC-sensitive by several treatments. GC-sensitive pediatric
B-cell leukemia was represented by the SUP-B15 line and adult B-cell leukemia by RS4;11 cells.
Kasumi-1 cells gave an example of the rare Dex-sensitive acute myeloblastic leukemia (AML). To
test the generality of the correlations in malignant cell gene sets, we compared with GC effects on
mouse non-transformed thymocytes.
Results: We identified a set of genes regulated by GCs in all GC-sensitive malignant cells. A
portion of these were also regulated in the thymocytes. Because we knew that the highly Dex-
resistant CEM-C1–15 cells could be killed by CVZ, we tested these cells with the latter steroid and
again found that many of the same genes were now regulated as in the inherently GC-sensitive cells.
The same result was obtained when we converted the Dex-resistant clone to Dex-sensitive by
treatment with forskolin (FSK), to activate the adenyl cyclase/protein kinase A pathway (PKA).
Conclusion: Our results have identified small sets of genes that correlate with GC-sensitivity in
cells from several hematologic malignancies. Some of these are also regulated in normal mouse
thymocytes.
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Background
This study was designed to find whether a common set of
GC-regulated genes would be found in cell lines from sev-
eral types of GC-sensitive malignancies. Several studies of
malignant cells sensitive to GC-driven apoptosis identi-
fied various candidate genes regulated by GCs [1-5]. Such
regulation precedes the final, irreversible activation of the
apoptotic machinery. Though some genes had been
detected in more than one study, detailed comparisons
are difficult due to differing gene array platforms, bioin-
formatics methods, and cell conditions used. To avoid
these problems we previously compared the genes regu-
lated in a set of closely related clones from the CEM line
of CD4, CD8 double-positive pediatric acute lymphoblas-
tic leukemia (ALL) [6], discerning a set of genes regulated
specifically in two clones sensitive to Dex-evoked apopto-
sis (CEM-C7–14 and CEM-C1–6) and not in a closely
related Dex-resistant clone (CEM-C1–15). We now carry
this work further. Treatment of the resistant clone with the
phenylpyrazolo-steroid CVZ, a selective modulator of GR
action [7], can provoke cell death [8-10]. Earlier work had
also shown that CEM-C1–15, and its parental clone CEM-
C1, can be converted to GC-sensitivity by activating the
PKA pathway [11,12]. We therefore were able to compare
the sets of genes regulated in C1–15 cells by Dex, which
does not activate apoptosis, with those in the same cells
treated with CVZ or converted to Dex-sensitive by activa-
tion of PKA. To ask whether overlapping gene sets would
be found regulated in other types of malignant GC-sensi-
tive cells, we selected three cell lines already known to be
killed by GCs [13,14] and derived from other lineages.
SUP-B15 is a B-cell, Philadelphia chromosome positive
pediatric ALL line grown from bone marrow blasts. SUP-
B15 cells express multiple B-cell, but not T-cell lineage
markers [15]. The RS4;11 line, representing an adult form
of ALL, was established from the bone marrow of a 32-
year old Caucasian female ALL patient in relapse [16].
These cells are characterized by the t(4;11) chromosomal
abnormality. Kasumi-1 is an acute myeloblastic leukemia
(AML) originally obtained from the peripheral blood of a
7-year old Japanese male [17]. The cells contain a t(8;21)
chromosomal abnormality which results in the expres-
sion of the AML1-ETO fusion protein, shown to bestow
sensitivity to both extrinsic and intrinsic apoptotic mech-
anisms in leukemic cells [18]. These myeloid cells possess
the highly unusual property for AML of apoptotic sensitiv-
ity to GCs [14]. As we found that indeed, a certain limited
group of genes were GC-regulated in all the cells under
conditions leading to GC-dependent apoptosis, we
extended our process by comparing the above gene sets
with genes regulated by GCs in mouse thymocytes, exqui-
sitely GC-sensitive non-transformed cells.
A smaller set of genes were concordant with those found
in the malignant human samples. Given that the experi-
ments were done over a considerable period of time, and
with evolving gene chip platforms, it is remarkable that a
distinct set of genes were found to be GC-regulated during
the pre-apoptotic phase, in cell lines from a variety of
human GC-sensitive hematologic malignancies. While
surely incomplete, the gene set found to be regulated in
every instance could be useful in identifying GC-sensitive
hematologic malignancies, if tested in clinical samples.
We present it now to be of use to others engaged in exam-
ining such samples, noting that GC response is often also
a predictor for response to many chemotherapies [19,20].
Results
Comparison of time course of GC-dependent cell death in 
several sub-types of human leukemias
We have shown with CEM cells that although steroids
must be continually present, their effects are reversible for
many hours preceding the irreversible commitment to
apoptosis. To validate their sensitivity of each cell type to
GCs and define the limit of the pre-apoptotic, reversible
"lag" phase, we treated with Dex or CVZ and followed via-
ble cells over time. In preliminary experiments we deter-
mined the GC concentrations that maximized the
apoptotic effect for each cell type (Methods). Counts of
viable cells from GC-treated samples were compared to
their matched vehicle controls (Fig. 1). Though its length
varied, each human cell line showed a pre-apoptotic "lag"
phase, during GC treatment of many hours, after which
increased cell death was observed, except for resistant
clone CEM-C1–15. When these were treated with CVZ or
converted to Dex-sensitive through PKA stimulation [12],
they also showed a lag. SUP-B15 cells were the most rap-
idly sensitive to GC; at a concentration of 10-7 M, Dex
reduced viable cell numbers to 50% of controls by 24
hours. Sensitive clones CEM-C7–14 and CEM-C1–6 (the
latter a spontaneous revertant from a resistant clone)
required the longest period (40 hours) of exposure to GC
before initiation of the apoptotic response. As we had
observed previously for CEM-C7–14 cells, treatment with
CVZ, a more potent GC with the ability to selectively
modulate GR action [7], increased cell death over that by
Dex. Both RS4;11 and Kasumi-1 cells reacted similarly in
regard to timing, but with differences in sensitivity, as the
Dex concentration required for maximum apoptotic
potency of Kasumi-1 cells was 10-fold less than for
RS4;11. Only a brief meeting report documented the GC-
sensitivity of SUP-15 and RS4;11 cells [13]. Our results
confirm and extend that report.
As is well known, primary mouse thymocytes in vitro rap-
idly respond to GCs with overt apoptosis [21]. We found
that under our experimental conditions, apoptosis of thy-
mocytes began after about 1.5 hours of continued expo-
sure in vitro to 10-7 M Dex (data not shown). Together,
these data confirm and/or extend prior reports and estab-Cancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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Glucocorticoids kill multiple sub-types of leukemia Figure 1
Glucocorticoids kill multiple sub-types of leukemia. Cells were seeded in triplicate at a starting density of 1 × 105 cells/
ml and subsequently treated with vehicle or various concentrations of Dex (C7–14 and C1–15, symbol, open circle) or CVZ 
(C7–14 and C1–15, symbol, closed triangle). Dex-resistant CEM-C1–15 cells were restored to sensitivity by treatment with 
FSK and Dex (symbol, closed square, note: the "lag" time for this drug combination preceded the initial 24 hour count – dashed 
line 0–24 hours). Samples were analyzed by Trypan blue exclusion assay at various time-points thereafter. Presented is the per-
cent of viable cells compared to matched control for the average of three independent replicates from vehicle vs. GC-treated 
at the time of evaluation. Error bars represent one standard deviation from the mean.
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RS4;11 – Adult B-ALL
CEM-C1-6 – Pediatric T-ALL
SUP-B15 – Pediatric B-ALL
Kasumi-1 – Pediatric AML
CEM-C7-14 – Pediatric T-ALL
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lish the dose and timing parameters used during the
remainder of the studies.
Sequential comparison of gene expression
For gene expression comparisons of all the malignant
lines, cells were taken for RNA extraction during the late
lag phase of pharmacological treatment, that is before
overt apoptosis and at a time that removal of steroid
would allow recovery of virtually all cells. This corre-
sponded to the time at which empirical data showed a
small fraction of the cells exhibiting phosphatidylserine
eversion by annexin-v assay. Since thymocytes in primary
culture are not growing, we extracted them after 1.5 hours
of exposure to Dex, a time when cell viability did not dif-
fer appreciably from controls.
The data from all experiments were analyzed in a concate-
nated series (Fig. 2). In overview, the sequence was: 1)
identification of those genes regulated ≥ 1.2-fold in every
CEM cell type under conditions that produced GC-
dependent apoptosis; 2) notation (asterisk, Table 1 and
Additional file 1) of those genes found similarly regulated
in Dex-treated but apoptosis-resistant CEM-C1–15 cells;
3) retention of genes regulated in CEM-C1–15 cells but in
the opposite sense from the GC-sensitive cells; 4) applica-
tion of Spotfire® statistical software to the regulated genes
common to CEM cells under all GC-sensitive conditions.
In Additional file 1, all the genes from step 1 are retained,
with notation if not unique to GC-sensitive cells, (e.g.
seen in CEM-C1–15). This resulted in a "signature" list of
genes always regulated in CEM cells under conditions in
which they were GC-sensitive (Fig. 2A). Usually, these dif-
ferences in mRNA levels were found to be statistically sig-
nificant.
Similarly, a "signature" gene set was derived for GC sensi-
tivity for all the leukemic cell lines: 1) compile genes reg-
ulated  ≥ 1.2-fold in every cell line, without regard to
statistical significance; 2) annotate genes Dex-regulated in
resistant C1–15 cells; 3) apply statistics. Genes regulated
similarly in every GC-sensitive cell type (Fig. 2B, C) com-
prise a possible "signature" for multiple leukemias. Again,
in most cases these were found statistically significant.
Separately, each gene set was compared to the genes regu-
lated by Dex in mouse thymocytes, to see whether some
were also present in the pre-apoptotic phase in non-trans-
formed mammalian cells.
Comparison of CEM cell clones reveals a signature for GC-
evoked apoptosis
GC-sensitive clones CEM-C7–14 and CEM-C1–6 were
treated in triplicate with vehicle alone or 10-6 M Dex.
CEM-C7–14 cells were also treated with the more potent
GR modulator CVZ. The CEM-C1–15 sister clone is resist-
ant to as much as 4.0-6 Dex but can be killed by CVZ.
Therefore these cells were treated with 10-6 M Dex or 10-6
M CVZ. Alternatively, we made use of the fact that CEM-
C1–15 cells can be converted to Dex-sensitive by activat-
ing the adenyl cyclase/PKA signaling pathway [12] and
(Fig. 1). We refined the gene set obtained from the ster-
oids-only treatments by adding the requirement that they
were also regulated in C1–15 cells after FSK plus Dex
exposure. (See Fig. 2A, solid box.)
Initially, all genes were listed whose mRNAs if "present"
as judged by Affymetrix software, were changed 20% or
more in the two Dex-treated, Dex-sensitive clones, in one
of these treated with 10-fold less CVZ, in the Dex-resistant
clone treated with high-dose CVZ, and in the Dex-resist-
ant clone treated with FSK plus Dex. After this list was pre-
pared, the data was evaluated statistically with the
exception of the FSK-sensitized C1–15 cell samples, for
which only duplicate experiments were performed. This
analysis resulted in 96 regulated genes, of which 48 were
Flow chart of various comparative schemes elucidates multi- ple GC-mediated gene signatures Figure 2
Flow chart of various comparative schemes eluci-
dates multiple GC-mediated gene signatures. (A) 
CEM Signature: All genes regulated in common in the same 
sense in GC-treated CEM-C7–14, CEM-C1–6, CEM-C1–15 
CVZ, and CEM-C1–15 Dex plus FSK cells were obtained 
(solid line box). This list was subsequently compared to Dex-
treated resistant CEM-C1–15 cells and to mouse thymo-
cytes. (B) Multiple Leukemia Signature: All genes regulated in 
common in the same sense in GC-treated CEM-C7–14, 
CEM-C1–6, RS4;11, SUP-B15, and Kasumi-1 cells were 
obtained (dashed line box). As before, this list was compared 
to Dex-treated resistant CEM-C1–15 cells and to mouse thy-
mocytes. (C) Composite Signature: All genes regulated in 
common in the same sense in GC-treated CEM-C7–14, 
CEM-C1–6, RS4;11, SUP-B15, Kasumi-1, CEM-C1–15 CVZ, 
and CEM-C1–15 Dex plus FSK were compiled into a final list 
(spotted line box). This list was compared to Dex-treated 
resistant CEM-C1–15 and to mouse thymocytes.
CEM-C7-14 Dx
CEM-C1-6 Dx
CEM-C7-14 CVZ
CEM-C1-15 CVZ
C1-15 Dx + FSK
A
SUP-B15 Dx
Kasumi-1 Dx
RS4;11 Dx
B
CCancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
Page 5 of 15
(page number not for citation purposes)
Table 1: Gene expression signature for GC-sensitivity in CEM cells. (Signaling Network Genes)
Sensitive Sensitive Sensitive Sensitive Resensitized Resistant
Name Description C7–14 Dx C7–14 Z C1–6 Dx C1–15 Z C1–15 Dx+F C1–15 Dx
AK2 adenylate kinase 2 -1.4 -1.7 -1.6 -1.6 -1.4 *
ARHGEF7 Rho guanine nucleotide exchange factor 
(GEF) 7
1.3 1.4 1.3 1.3 1.8 1.2
BCL2L11 BCL2-like 11 (apoptosis facilitator) 3.1 14.5 5.9 1.3 1.8 *
CALR calreticulin -1.9 -1.7 -1.6 -1.4 -1.6 -1.3
CDC6 CDC6 cell division cycle 6 homolog (S. 
cerevisiae)
-1.3 -1.2 -1.5 -1.3 -1.3 -1.3
DDIT4 DNA-damage-inducible transcript 4 4.4 3.4 2.5 1.2 4.4 1.5
FGFR1 fibroblast growth factor receptor 1 1.6 3.1 1.4 1.7 1.7 1.3
FKBP4 FK506 binding protein 4, 59 kDa -1.9 -2.1 -1.3 -1.5 -1.6 *
FKBP5 FK506 binding protein 5 6.6 11.2 4.4 3.8 2.9 2.8
HDAC1 histone deacetylase 1 -1.4 -1.2 -1.2 -1.3 -1.2 -1.3
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene 
homolog
-1.3 -1.4 -1.3 -1.4 -1.4 *
ID1 inhibitor of DNA binding 1, dominant 
negative helix-loop-helix protein
-2.6 -1.7 -1.2 -1.9 -1.6 -1.4
IFRD1 interferon-related developmental regulator 1 -1.8 -1.2 -1.6 -1.6 -1.3 *
IL7R interleukin 7 receptor 8.3 18.0 6.3 1.4 2.5 *
ITGA6 integrin, alpha 6 5.0 10.2 2.4 6.6 2.8 1.6
MAP4 microtubule-associated protein 4 -1.3 -1.8 -1.7 -1.3 -1.3 *
MT1A metallothionein 1A (functional) 1.3 1.3 2.2 1.4 1.4 *
MTHFD1 methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1
-1.4 -1.9 -1.5 -1.5 -1.2 *
MYC v-myc myelocytomatosis viral oncogene 
homolog (avian)
-3.8 -4.6 -3.6 -1.4 -2.2 *
NFKBIA nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha
3.0 3.4 2.8 1.9 1.5 1.3
NME1 non-metastatic cells 1, protein (NM23A) 
expressed in
-1.5 -2.2 -1.6 -1.4 -1.3 *
NR3C1 nuclear receptor subfamily 3, group C, 
member 1 (glucocorticoid receptor)
4.2 6.6 2.1 1.7 1.6 *
OGT O-linked N-acetylglucosamine (GlcNAc) 
transferase
1.3 1.7 2.0 1.6 1.3 *
PIAS2 protein inhibitor of activated STAT, 2 1.2 1.4 1.5 2.0 1.3 *
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 
1 (p85 alpha)
2.5 2.4 1.7 2.0 1.9 *
RBMS1 RNA binding motif, single stranded 
interacting protein 1
1.4 2.0 1.7 1.6 1.5 1.6
SCARB1 scavenger receptor class B, member 1 -1.7 -2.2 -1.2 -1.5 -1.2 -1.3
SRM spermidine synthase -1.8 -3.3 -1.7 -1.4 -1.4 *
TAGLN2 transgelin 2 -1.4 -2.0 -1.3 -1.2 -1.2 *
TRAF3IP2 TRAF3 interacting protein 2 1.6 2.1 1.8 1.5 1.4 1.3
TSC22D3 TSC22 domain family, member 3 33.1 74.0 20.4 7.4 14.3 5.0
TXNIP thioredoxin interacting protein 2.8 3.4 3.7 1.4 2.0 1.2
UBE2S ubiquitin-conjugating enzyme E2S -1.6 -1.6 -1.3 -1.6 -1.3 *
VCL vinculin 1.8 1.6 1.9 1.3 1.5 *
YAF2 YY1 associated factor 2 1.8 2.4 1.6 1.7 1.3 1.6
Regulated transcripts from vehicle or GC-treated samples were evaluated and compared using Spotfire® and Ingenuity® bioinformatics software. 
Selection criteria for each gene were as follows: probe called present (Methods) on the microarray and regulated ≥ 1.2-fold (net 20% change). GC-
mediated transcripts regulated in common in the same direction among sensitive CEM-C7–14 Dex (C7–14 Dx) and CVZ (C7–14 Z), CEM-C1–6 
(C1–6 Dx), CEM-C1–15 CVZ (C1–15 Z), and CEM-C1–15 Dex plus FSK (C1–15 Dx+F) cells were obtained. This comparison resulted in 96 
regulated genes (see Additional file 1). This list was subsequently compared to Dex-treated resistant CEM-C1–15 cells (C1–15 Dx). Shown is a 
subset of 35 genes from the original 96 that could be linked via a signaling network (symbol, closed diamond in Additional file 1). Bold type indicates 
statistically significant regulation p ≤ 0.05 between means of vehicle vs. GC-treated. Symbol, asterisk = gene "absent" by selection criteria.Cancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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induced and 48 were repressed (see Additional file 1). Sta-
tistical analysis of the means from both control and GC-
treated samples were used to generate p-values (bold type
in the table). Of the 96 genes, 43 showed a suggestion of
weak regulation by Dex in the resistant clone CEM-
C1–15, though usually without reaching statistical signif-
icance. Of the 43, GSK3B and IL10RB were found to be
regulated in opposite directions between Dex-sensitive
and -resistant CEM clones. Through the use of Ingenuity®
pathway analysis, a signaling network was revealed, link-
ing 35 of the 96 genes. (Fig. 3, Table 1, the 35 also are des-
ignated by, closed diamond in Additional file 1). It is
obvious from the network that two major signal transduc-
tion nodes exist: 1) affiliation with induction of NR3C1 –
the GR; and 2) affiliation with repression of MYC. Minor
signaling nodes appear routed through HDAC1, NFKBIA,
and PIK3R1. These data suggest that the gene set identified
includes genes involved in a relevant signaling pathway,
and are not just a random assortment that happen to be
GC-regulated. In an independent study of the time course
of response in CEM-C7–14 exposed to Dex, we found that
the change in these genes was progressive over the interval
of steroid exposure (M.S. Webb and E.B. Thompson, man-
uscript submitted).
To determine which of the conserved GC-regulated genes,
if any, were also regulated in a naturally non-transformed
sensitive lymphoid cell system, we compared regulation
between human CEM cells and mouse thymocytes. The
latter are exquisitely sensitive to GCs, undergoing apopto-
sis within hours of exposure instead of days as for the
malignant cells [21]. Examination of the conserved gene
A signaling network links genes regulated by GCs in CEM cells Figure 3
A signaling network links genes regulated by GCs in CEM cells. Ingenuity® bioinformatics pathway analysis tool was 
used to connect a subset of 35 genes from the CEM signatory list (Table 1, and symbol, closed diamond in Additional file 1) 
based upon a database of published observations. Symbols for genes representing specific categories of cellular molecules as 
well as interactive relationships are depicted in the legend. Color gradations are based upon gene regulation at the fold-change 
level. Red color: induced gene; green color: repressed gene. Fold-change data from CEM-C7–14 cells treated with Dex are 
presented as representative of the CEM signature.
Induced gene
Repressed geneCancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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set yielded 34 transcripts that were regulated in thymo-
cytes also. However, of these, only 20 were regulated in
the same sense in the thymocytes; the other 14 were regu-
lated in the opposite sense. (see Additional file 1, symbol,
closed circle). These data suggest that there is a shared
pathway of GC-regulated genes, relevant to apoptosis, in
both malignant and normal mammalian lymphoid cells.
Genes regulated by GCs in multiple sub-types of GC-
sensitive leukemias show a common genetic signature
To test for a common signature for GC-sensitivity among
various leukemic cells, we compared cell lines represent-
ing three types of GC-sensitive leukemias with the CEM
cells (Fig. 2B, dashed-line box). From literature reports of
GC-sensitivity [13,14], we chose SUP-B15 (pediatric B-cell
ALL), RS4;11 (an adult B-cell ALL), and Kasumi-1 (a spe-
cial type of GC-sensitive pediatric AML). As in CEM cells,
preliminary experiments established both optimal con-
centrations of GCs and timing of phosphatidylserine
membrane eversion for each cell line to capture gene
expression data before irreversible onset of apoptosis.
Comparison of GC-sensitive CEMs with RS4;11, SUP-
B15, and Kasumi-1 identified 122 genes, 52 induced and
70 repressed, all regulated ≥ 1.2-fold in the same sense in
all cell lines. These were then tested for statistical signifi-
cance (see Additional file 2). Of these genes, 26 were also
found to be regulated by Dex in the Dex-resistant CEM-
C1–15 cells in the same sense and thus are not of them-
selves both necessary and sufficient for evoking apoptosis.
Four genes, FOXO3A, SFRS2, SLC7A1, and PAI-RBP1 were
regulated in a different sense (e.g. induced vs. repressed)
between sensitive cells and the resistant CEM-C1–15 cells.
As had been done with CEM cells alone, the 122 gene set
was compared to the mouse thymocyte data. Thirty-three
genes were also found regulated in the thymus; 19 in the
same sense as in the GC-sensitive leukemias and 14 in the
opposite sense (see Additional file 2 symbol, closed cir-
cle).
Quantitative real-time PCR confirms GC-regulation of an 
induced and repressed gene in multiple hematologic 
malignancies
As proof-of-principle that our approach was valid, we con-
firmed the regulation of two genes established as impor-
tant for GC-sensitivity: 1) the pro-apoptotic Bcl-2 family
member (BCL2-like 11, BCL2L11/Bim), a GC-induced
gene; and 2) ornithine decarboxylase (ODC1), a MYC-
dependent, GC-repressed gene [22-24] in two cell lines
evaluated by microarray (CEM-C7–14 and SUP-B15, see
Additional file 2) and the GC-sensitive multiple myeloma
cell line OPM-2, which was not evaluated for global gene
changes in this array study. Fig. 4 shows the results from
real-time PCR assays for BCL2L11 and ODC1 regulation
in CEM-C7–14, SUP-B15, and OPM-2 cells treated with
Dex for 24 hours. Both genes were confirmed as regulated,
one induced and the other repressed in all three cell lines.
Refinement of the GC-sensitivity signature by comparison 
of genes regulated in naturally sensitive and resistant-
restored-to-sensitive cells
The gene set derived by comparing responses in all the cell
clones and lines inherently sensitive to GC-evoked apop-
tosis (Fig. 2B) was compared to the set regulated by Dex-
resistant CEM-C1–15 cells treated with high concentra-
tion CVZ (10-6 M) or to Dex in combination with FSK, the
activator of the adenyl cyclase/PKA pathway (Fig. 2C,
large dotted-line box). Genes regulated in common under
all of these conditions were identified as possible signifi-
cant players in the role of the GC-mediated apoptotic
response (Table 2). A total of 27 genes met these criteria,
and of these 17 were shown to be induced while 10 were
observed as repressed. Nearly all genes were found to be
statistically significantly regulated by GC (bold type)
where the calculation could be applied. In Dex-resistant
CEM-C1–15 cells, 14 of these 27 genes were also seen to
be regulated by Dex.
When we compared these 27 genes to Dex-treated thymo-
cytes to obtain those conserved between human and
mouse (Table 3) we found 10 genes (8 induced, 2
Quantitative real-time PCR confirms regulation of BCL2L11/ Bim and ODC1 by Dex in multiple hematologic malignancies Figure 4
Quantitative real-time PCR confirms regulation of 
BCL2L11/Bim and ODC1 by Dex in multiple hemato-
logic malignancies. CEM-C7–14, SUP-B15, and OPM-2 
cells were diluted to 4 × 105 cells/ml and treated with etha-
nol vehicle, 10-6 M Dex (C7–14 and OPM-2), or 10-7 M Dex 
(SUP-B15) for 24 hours. RNA was extracted and qRT-PCR 
was performed for BCL2L11/Bim and ODC1 transcripts. The 
log2 ratio for BCL2L11/Bim and ODC1 are presented. Regu-
lation of both transcripts was determined to be statistically 
significant p ≤ 0.05 when compared to the internal standard 
after three independent PCR reactions.
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Table 2: Gene expression signature for GC-sensitivity among sensitive and Dex-resistant-restored-to-sensitive leukemias
GC-response Sen. Sen. Sen. Sen. Sen. Sen. Sen. Resen. Res.
Patient-
derived line
Ped. Ped. Ped. Adult Ped. Ped. Ped. Ped. Ped.
Cell lineage T-cell T-cell T-cell B-cell B-cell Myeloi
d
T-cell T-cell T-cell
Sub-type of 
leukemia
ALL ALL ALL ALL ALL AML ALL ALL ALL
Name Description C7–14 Dx C7–14 Z C1–6 Dx RS4 Dx SUP Dx Kas Dx C1–15 Z C1–15 Dx+F C1–15 Dx
AK2 adenylate kinase 2 -1.4 -1.7 -1.6 -1.4 -2.2 -3.3 -1.6 -1.4 *
BCL2L11 BCL2-like 11 (apoptosis 
facilitator)
3.1 14.5 5.9 1.2 3.1 5.1 1.3 1.8 *
BTG1 B-cell translocation gene 1, 
anti-proliferative
9.3 9.1 4.4 1.2 3.9 8.8 3.3 1.7 1.9
CD53 CD53 antigen 3.1 3.4 3.2 1.4 3.1 7.2 1.5 1.8 1.4
CDC6 CDC6 cell division cycle 6 
homolog (S. cerevisiae)
-1.3 -1.2 -1.5 -1.7 -2.9 -4.7 -1.3 -1.3 -1.3
DDIT4 DNA-damage-inducible 
transcript 4
4.4 3.4 2.5 5.5 4.6 22.4 1.2 4.4 1.5
DSCR1 Down syndrome critical 
region gene 1
5.0 8.2 4.8 1.5 7.7 7.9 1.4 1.6 *
EIF3S9 eukaryotic translation 
initiation factor 3, subunit 9 
eta
-1.5 -2.2 -1.3 -1.2 -2.0 -2.2 -1.2 -1.2 *
FADS1 fatty acid desaturase 1 -1.5 -4.1 -1.9 -1.5 -1.5 -1.8 -1.9 -1.3 -1.3
FKBP5 FK506 binding protein 5 6.6 11.2 4.4 7.0 21.4 13.7 3.8 2.9 2.8
IDH3A isocitrate dehydrogenase 3 
(NAD+) alpha
-1.5 -1.3 -1.5 -1.6 -1.7 -2.4 -1.2 -1.3 *
MARS methionine-tRNA 
synthetase
-1.5 -1.6 -1.5 -1.5 -2.2 -2.2 -1.2 -1.3 *
MEP50 WD repeat domain 77 -1.7 -1.4 -1.8 -1.8 -1.5 -1.4 -1.5 -1.3 *
MT1X metallothionein 1× 1.4 2.1 2.2 1.6 1.8 1.7 1.3 1.4 *
NFKBIA NFκB inhibitor, alpha 3.0 3.4 2.8 1.9 2.5 5.5 1.9 1.5 1.3
OGT O-linked N-
acetylglucosamine (GlcNAc) 
transferase
1.3 1.7 2.0 2.0 1.3 2.1 1.6 1.3 *
PA2G4 proliferation-associated 
2G4, 38 kDa
-1.7 -1.9 -1.7 -1.3 -2.5 -3.5 -1.3 -1.2 *
PARD3 par-3 partitioning defective 
3 homolog (C. elegans)
1.6 1.7 1.4 2.5 1.5 3.0 1.3 1.4 *
PRG1 proteoglycan 1, secretory 
granule
2.6 4.5 3.2 2.7 1.5 2.7 1.2 1.9 1.6
RAPGEF2 Rap guanine nucleotide 
exchange factor (GEF) 2
1.7 1.7 1.4 1.8 2.0 4.2 1.3 1.3 *
RBMS1 RNA binding motif, single 
stranded interacting protein 
1
1.4 2.0 1.7 3.0 4.3 2.3 1.6 1.5 1.6
SCARB1 scavenger receptor class B, 
member 1
-1.7 -2.2 -1.2 -1.4 -4.9 -33.3 -1.5 -1.2 -1.3
TFPI tissue factor pathway 
inhibitor
3.1 5.4 1.9 4.9 9.6 24.6 2.0 1.8 1.7
TSC22D3 TSC22 domain family, 
member 3
33.1 74.0 20.4 5.2 17.5 20.0 7.4 14.0 5.0
TXNIP thioredoxin interacting 
protein
2.8 3.4 3.7 10.0 7.7 2.1 1.4 2.0 1.2
YAF2 YY1 associated factor 2 1.8 2.4 1.6 1.7 1.9 5.8 1.7 1.3 1.6
ZNF259 zinc finger protein 259 -1.4 -1.5 -1.8 -1.2 -1.3 -1.6 -1.3 -1.2 *
The 122 genes obtained from comparison of both pediatric (Ped.) and adult GC-sensitive (Sen.) leukemias (see Additional file 2) were compared to Dex-resistant, 
CVZ-sensitive CEM-C1–15 CVZ (C1–15 Z), and resistant-restored-to-sensitive (Resen.) CEM-C1–15 Dex plus FSK (C1–15 Dx+F) regulated transcripts. These 
comparisons resulted in 27 genes regulated in the same sense among all naturally GC-sensitive and resistant-restored-to-sensitive human leukemias. This list was 
subsequently compared to Dex-treated resistant (Res.) CEM-C1–15 cells (C1–15 Dx). Bold type indicates statistically significant regulation p ≤ 0.05 between 
means of vehicle vs. GC-treated. Symbol, asterisk = gene "absent" by selection criteria.Cancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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repressed). Two of the 10 were regulated in the opposite
sense in the mouse cells (Table 3, OGT and PA2G4, sym-
bol, closed circle). Six of the 10 genes were also regulated
by Dex even in resistant CEM-C1–15 cells. All 10 however,
were regulated in CEM-C1–15 cells treated with CVZ or
with FSK plus Dex. We conclude that certain genes are reg-
ulated by GC in normal mouse thymocytes as they are in
several types of GC-sensitive human leukemias. Among
the leukemia types tested, we have identified a set of genes
that appear to give a partial profile for sensitivity for GC-
driven apoptosis. These genes may give clues to the pre-
apoptotic pathway. We hope that this GC-sensitive profile
encourages application to clinical samples.
Discussion
Seeking the genes responsible for the build up over time
to GC-mediated apoptosis, we have used microarrays to
uncover genetic "signatures". By sequentially screening
transcripts regulated in common between various sub-
types of sensitive, resistant, and resistant-restored-to-sen-
sitive leukemic human cell lines and even non-malignant
mouse thymocytes, we have discovered a small list of
genes regulated in common among all GC-sensitive con-
ditions. We believe these genes to be at the core of the
apoptotic signature to GCs. As might be expected, cell
type-specific subsets were found, and thymocytes showed
fewer genes regulated in common with the GC-sensitive
malignant cells. Among the signatory genes we find BCL2-
like 11 apoptosis facilitator (BCL2L11, Bim), Down syn-
drome critical region gene 1 (DSCR1), Thioredoxin-inter-
acting protein (TXNIP, VDUP1), DNA-damage-inducible
transcript 4 (DDIT4, RTP801, REDD1, or dig2), Nuclear
factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha (NFKBIA), FK506 binding protein 5
(FKBP5), and exclusive to the examined human leuke-
mias GC-induced leucine zipper (TSC22D3, DSIPI, or
GILZ), all of which have been investigated for possible
roles in GC-stimulated apoptosis [22,25-31]. These prior
studies show both anti- and pro-apoptotic actions for
many of these genes studied in isolation, but no study
thus far has been able to link particular genes together to
fill in all the critical gaps in the apoptotic mechanism. Our
results suggest that this is because these genes work as part
of a network and only in the context of the particular cel-
lular network in which they are found can their action be
fully understood. Further experiments manipulating more
than one gene simultaneously will be necessary to close
these gaps in such networks. Nonetheless, the fact that a
relatively small set of genes are implicated in several
leukemic lineages speaks strongly to the universality of
the key genes systems at work in GC-dependent cell death.
Core profile genes have been shown relevant to GC-
dependent apoptosis
Several genes in the set shared by all the GC-sensitive
leukemic cells tested (see Table 2 and Additional file 2)
Table 3: Conserved gene expression signature for GC-sensitivity in thymocytes and multiple leukemias
GC-response Sen. Sen. Sen. Sen. Sen. Sen. Sen. Sen. Resen. Res.
Mouse vs. 
Human
Mouse Ped. Ped. Ped. Adult Ped. Ped. Ped. Ped. Ped.
Cell lineage T-cell T-cell T-cell T-cell B-cell B-cell Myeloid T-cell T-cell T-cell
Type of cell Thymocyte ALL ALL ALL ALL ALL AML ALL ALL ALL
Name Description Opp. R C57/BL6 
Dx
C7–14 
Dx
C7–14 
Z
C1–6 
Dx
RS4 
Dx
SUP 
Dx
Kas 
Dx
C1–15 
Z
C1–15 
Dx+F
C1–15 
Dx
BCL2L11 BCL2-like 11 (apoptosis facilitator) 1.8 3.1 14.5 5.9 1.2 3.1 5.1 1.3 1.8 *
CDC6 CDC6 cell division cycle 6 homolog 
(S. cerevisiae)
-1.2 -1.3 -1.2 -1.5 -1.7 -2.9 -4.7 -1.3 -1.3 -1.3
DDIT4 DNA-damage-inducible transcript 4 2.9 4.4 3.4 2.5 5.5 4.6 22.4 1.2 4.4 1.5
DSCR1 Down syndrome critical region 
gene 1
1.3 5.0 8.2 4.8 1.5 7.7 7.9 1.4 1.6 *
FKBP5 FK506 binding protein 5 1.7 6.6 11.2 4.4 7.0 21.4 13.7 3.8 2.9 2.8
NFKBIA NFκB inhibitor, alpha 1.5 3.0 3.4 2.8 1.9 2.5 5.5 1.9 1.5 1.3
OGT O-linked N-acetylglucosamine 
(GlcNAc) transferase
-1.5 1.3 1.7 2.0 2.0 1.3 2.1 1.6 1.3 *
PA2G4 proliferation-associated 2G4, 38 
kDa
1.2 -1.7 -1.9 -1.7 -1.3 -2.5 -3.5 -1.3 -1.2 *
PRG1 proteoglycan 1, secretory granule 1.6 2.6 4.5 3.2 2.7 1.5 2.7 1.2 1.9 1.6
TXNIP thioredoxin interacting protein 2.6 2.8 3.4 3.7 10.0 7.7 2.1 1.4 2.0 1.2
To obtain genes regulated by GCs in a conserved manner in both pediatric (Ped.) and adult leukemias, the 27 genes regulated in the same sense among all naturally GC-
sensitive (Sen.) and resistant-restored-to-sensitive (Resen.) human leukemias (Table 2) were compared to mouse thymocytes (C57/BL6 Dx). This analysis identified 10 genes, 
2 of which were regulated in an opposite sense regulation between human and mouse indicated by (Opp. R, symbol, closed circle). This list was also compared to Dex-treated 
resistant (Res.) CEM-C1–15 cells (C1–15 Dx). Bold type indicates statistically significant regulation p ≤ 0.05 between means of vehicle vs. GC-treated. Symbol, asterisk = gene 
"absent" by selection criteria.Cancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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have been demonstrated to be important for GC-depend-
ent apoptosis. These genes include BCL2L11/Bim, DDIT4,
DSCR1, TXNIP, NFKBIA, FKBP5, and TSC22D3/DSIPI/
GILZ. In 1999, Bouillet et al. [25] observed that lym-
phocytes derived from Bim knockout mice were partially
resistant to Dex-mediated apoptosis. Subsequently, we
noted that Bim was upregulated by GC exclusively in two
Dex-sensitive CEM clones [6]. Independently, this finding
was confirmed in CEM cells and extended to mouse lym-
phoma lines [32]. Since then, Bim induction in response
to GCs has been shown in chronic lymphocytic leukemia
cells destined for apoptosis [33] and in thymocytes [34].
Recently, our finding that GCs activate p38 MAPK in both
human and mouse lymphoid cells [35] has been extended
to show an interaction between GC-mediated p38 MAPK
stimulation and the expression of Bim, linking these two
pro-apoptotic pathways in context to the GC signal trans-
duction system as well as enzymatic protein activity and
transcription [36]. We have demonstrated by qRT-PCR
and confirm here by microarray that CVZ, which causes
apoptosis in CEM-C1–15 cells, induces Bim in them,
whereas Dex, to which they are resistant, does not [7]. It
has also been shown that Bim regulation converges with
the PKA pathway [37] consistent with our findings of Bim
induction in the CEM-C1–15 cells restored to Dex-sensi-
tive by FSK activation of that pathway. The rise in Bim,
which occurs late in the lag phase, may be one of the final
precipitating factors initiating apoptosis.
Our data indicated that DSCR1, like Bim, was induced in
all GC-sensitive conditions in both human and mouse
indicating its importance in the apoptotic program regu-
lated by GCs. DSCR1 antagonizes the biological effects of
the phosphatase calcineurin by interacting with catalytic
subunit A and disrupting its downstream signaling path-
ways [38]. Data from glioblastoma cells suggests that in
some cell types at least, DSCR1 may also stabilize IkappaB
alpha, by an action independent of calcineurin [39].
TXNIP and DDIT4 regulate the redox state within the cell
[40,41]. This effect was tested and the induction of TXNIP
with the subsequent reduction in thioredoxin activity in
response to Dex was confirmed, in WEHI7.2 cells [28].
Our comparative study indicates TXNIP to be regulated in
all cells and conditions tested, but induction by Dex in the
Dex-resistant cell line was very weak (Table 3).
NFKBIA antagonizes the action of transcription factor
NFκB. We found NFKBIA to be induced by GCs in all sys-
tems tested, but like TXNIP, only weakly by Dex in resist-
ant C1–15 cells. Inhibition of NFκB has been correlated
with restoration of GC-sensitivity to resistant human
monocytic/macrophage THP1 and U937 cell lines [30].
Several reports have suggested the use of the inductive
response of the immunophilin FKBP5 (also known as
FKBP51) as a diagnostic tool for GC response in periph-
eral blood mononuclear, T- and B-lymphocytes, and the
highly Dex-resistant lymphoblastoid cell line IM-9 [42-
44]. We call attention to the fact that Dex strongly induced
FKBP5 in the resistant C1–15 cells. Thus FKBP5 induction
alone is not always an indicator of apoptotic sensitivity to
GC.
TSC22D3/DSIPI/GILZ was highly induced in all the
leukemic cells tested, regardless of apoptotic sensitivity or
resistance. Thus, as with FKBP5, GILZ induction alone
cannot be relied upon as an indicator of apoptotic sensi-
tivity to GCs.
The final gene sets that we have discovered are almost cer-
tainly incomplete, limited as they are by the numbers of
genes represented on the smallest microarray chips
employed. Thus our gene profile sets, while valid, may be
expanded by additional studies with more complete
arrays on larger chips. Nevertheless, the gene sets we have
identified provide an initial tool that can be tested as
prognostic indicators and almost certainly offer greater
reliability than a single gene, e.g. FKBP5 or GILZ.
Coincidence of regulated genes in varied leukemic cell 
types may provide the basis for prognostic screening
Therefore, we propose that our data offers the basis for
developing a prognostic panel to screen relevant patients
for the likelihood of an apoptotic response to GC. In at
least some leukemias, response to GC is also predictive of
response to overall chemotherapy [19,20]. Our work
identifies the commonality of certain genes regulated by
GCs in the apoptotically sensitive state of several leuke-
mias, regardless of lineage. We present in Additional file 3
the list of 191, (83 induced, symbol plus, 108 repressed,
symbol minus) genes regulated in common and specific
to each list from the CEM signature (see Additional file 1)
and the multiple cell line signature (see Additional file 2).
Though low cellular GR levels or GR mutations may
account for a fraction of GR-resistant leukemias, the
majority of GC-resistant cases are GR-positive [45-47]. In
one study, involving xenografts derived from pediatric
ALL patient biopsies, the failure of Bim to induce upon
exposure to GC was associated with the resistant pheno-
type [48]. Combining this marker with the additional
genes we have identified should strengthen the correla-
tions.
The differences in GC-regulated genes found between the
various types of leukemic cells examined may also be of
importance. Examination of Additional files 4, 5, 6, 7, 8
and 9 shows that groups of genes are GC-controlled spe-
cifically in the adult B-cell ALL RS4;11, pediatric AML
Kasumi-1, or pediatric B-cell ALL SUP-B15 lines. Since weCancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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were only able to examine one example of each of these
types, it would be premature to conclude that the regu-
lated genes found here as cell line-specific are representa-
tive of GC-apoptotic sensitivity in all leukemias of that
class. We provide here in the additional files the compar-
isons that reveal the seemingly cell type-specific regulated
genes, for the use of others and for the basis of wider-rang-
ing experiments.
Shared GC-dependent gene regulation in mouse thymo-
cytes and GC-sensitive leukemias speaks to a conserved
pathway for GC-evoked apoptosis in lymphoid and other
cells of hematologic origin. Since the "mouse chip" we
employed only contains 6,000 probes, its breadth of sam-
pling is limited compared to the human chips used. Even
so, a sub-set of regulated genes common to the GC-sensi-
tive human leukemic cell lines was also found to be regu-
lated in the thymocytes. This indicates a remarkable
underlying fundamental basis for the GC-dependent pre-
apoptotic pathway considering the many differences
between the systems: species, cells proliferating or not,
oncogenetically transformed or not, lymphoid or mye-
loid. Finding several genes in the leukemic cells that are
also regulated in the thymocyte system argues strongly for
an essential basic network involved in GC-dependent
apoptosis.
Conclusion
In this study we have identified genes regulated by GCs
using several apoptotic-sensitive cell lines and compared
them to resistant, and resistant-restored-to-sensitive
leukemic cells. We confirm and extend the brief meeting
report [13] of the GC-sensitivity of SUP-B15 and RS4;11
cells. We have also found that there is a conserved group
of genes regulated by GCs in common between cancer cell
lines and primary mouse thymocytes. We present a pre-
liminary genomic "signature" for apoptotic sensitivity to
GCs in leukemias, in hope that it can be tested for screen-
ing clinical samples.
Methods
Reagents
Dex and all other chemicals except CVZ, FSK, and DEPC-
treated water were purchased from Sigma-Aldrich (St.
Louis, MO). CVZ was obtained through the kind offices of
Dr. J. P. Raynaud, Roussel-UCLAF, Paris, France. FSK was
from Calbiochem (La Jolla, CA) and DEPC-treated water
was from Ambion (Austin, TX).
Cell culture
The CCRF-CEM cell line was originally derived from a
pediatric patient with ALL [49]. Highly Dex-sensitive
CEM-C7–14 and Dex-resistant CEM-C1–15 cell clones
were subcloned from the original C7 and C1 clones with-
out selective pressure. CEM-C1–6, a Dex-sensitive sponta-
neous revertant was derived from the Dex-resistant C1
parent [50]. CEM cells were grown in RPMI 1640 (Cellgro
Media Tech, Herndon, VA) pH 7.4 supplemented with 5%
heat-inactivated fetal bovine serum (FBS) (Atlanta Biolog-
icals, Norcross, GA). ALL cell lines RS4;11, SUP-B15, and
the AML cell line Kasumi-1 were obtained from the Amer-
ican Type Culture Collection (ATCC, Manassas, VA).
OPM-2 cells were originally derived from a patient with
multiple myeloma [51]. RS4;11 and Kasumi-1 cells were
grown in RPMI 1640 supplemented with 10 mM Hepes, 1
mM sodium pyruvate, and 10% FBS for RS4;11 or 20%
FBS for Kasumi-1. SUP-B15 were cultured in Iscove's mod-
ified Dulbecco's medium containing 4 mM L-glutamine,
0.05 mM 2-mercaptoethanol, and 20% FBS. OPM-2 cells
were grown in RPMI 1640 plus 10% defined FBS
(Hyclone, Logan, UT). Mouse experiments were per-
formed using sterile techniques under the approval and
guidance of UTMB's Institutional Animal Care and Use
Committee (IACUC) committee. Six 4-week old female
C57 Black 6 mice (Harlan Sprague Dawley, Indianapolis,
IN) were humanly euthanized using CO2 asphyxiation
with subsequent surgical extraction of the whole thymus.
The whole thymuses were deposited in a nylon mesh bag
constructed by sealing the sides of LAB PAK mesh sheets
(SEFAR America Inc., Kansas City, MO) and submerged in
a small volume of 37°C RPMI 1640 + 5% FBS in a sterile
35 × 10 mm plastic petri dish. Thymocytes were separated
by mechanical disruption of the thymus using sterile bent
forceps and abrading the tissue from all six mice. All cells
were cultured at 37°C in a humidified atmosphere of 95%
air, 5% CO2. All cells except the thymocytes were grown in
conditions ensuring logarithmic growth at the time of
addition of the steroids or other compounds. Cell viabil-
ity was determined by Trypan blue dye (Sigma-Aldrich)
exclusion through use of a manual hemacytometer or by
Vi-cell automated cell (Beckman Coulter, Miami, FL)
counting. To determine GC-sensitivity, cells were diluted
to 1 × 105 viable cells/ml in triplicate wells and exposed to
vehicle control ethanol or DMSO (< 0.1% at final concen-
tration) or various concentrations of Dex from 10-9 M to
10-6 M; thymocytes were exposed to 10-7 M Dex only. Pre-
vious experiments had established the optimal concentra-
tions of CVZ in CEM clones [7]. These experiments
resulted in the following GC concentrations: CEM-C7–14
= 10-6 M Dex, 10-7 M CVZ; CEM-C1–6 = 10-6 M Dex; CEM-
C1–15 = 10-6 M Dex, 10-6 M CVZ; RS4;11 = 10-6 M Dex;
SUP-B15 = 10-7 M Dex; Kasumi-1 = 10-7 M Dex; OPM-2 =
10-6 M Dex; and thymocytes = 10-7 M Dex. We have previ-
ously noted the optimal conditions for resensitization of
CEM-C1–15 cells to Dex through the use of FSK [12].
Preliminary experiments established the time of initial
Dex-mediated phosphatidylserine membrane eversion,
an early apoptotic feature for each cell type ([6] and data
not shown). Treatment of CEM cells with CVZ or Dex plusCancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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FSK was taken at this same time-point. Experiments were
performed in triplicate for both control and GC-treated
samples, except for CEM-C1–15 cells treated with CVZ,
for which three ethanolic and one DMSO 20 hour con-
trols were averaged and compared to three CVZ-treated
cultures and CEM-C1–15 samples treated with ethanolic/
DMSO vehicle or Dex plus FSK which were done in dupli-
cate. The gene expression profiles of ethanolic and
DMSO-treated cells did not differ significantly/greatly
between any of the samples. For microarray analysis of
each cell type, RNA was extracted at the time of phosphati-
dylserine membrane eversion: CEM cells = 20 hours,
RS4;11 = 24 hours, SUP-B15 = 24 hours, Kasumi-1 = 12
hours, and thymocytes = 1.5 hours.
RNA extraction
At the appropriate time-point (Cell culture) cells were har-
vested by centrifugation 200 × g for 10 minutes and proc-
essed according to the instructions with the RNeasy
extraction kit (Qiagen, Santa Clara, CA). The quality of
each RNA preparation was validated independently by the
UTMB Bioinformatics Core before its use.
Target labeling and hybridization
Affymetrix microarray probe labeling and target hybridi-
zation was carried out as previously described [6]. All
CEM cells were evaluated on HG_U95 Av2; RS4;11, SUP-
B15, and Kasumi-1 on HGU133 Plus 2.0; and mouse thy-
mocytes on U74Av2 Affymetrix GeneChip arrays. Gene-
Chip arrays were analyzed in the UTMB Bioinformatics
Core facility by Affymetrix GeneChip Suite software.
Bioinformatic analysis
Affymetrix pivot data files for all chips were imported into
Spotfire® functional genomics software package version
8.1 (Somerville, MA). Genes whose transcript levels per-
mitted a "present" call in ≥ 2 of 3 experiments were kept
for further evaluation in all except CEM-C1–15 treated
with Dex and FSK for which "present" was equal to 2 out
of 2 experiments. A fold change cut-off was set at 1.2, a net
20% change, for each regulated gene. The mean transcript
signal intensities corrected for baseline from triplicate (or
in some cases 4) independent experimental samples were
calculated, and control vs. treated p-values were deter-
mined except for CEM-C1–15 cells treated with Dex and
FSK. A p-value of ≤ 0.05 was taken as statistically signifi-
cant. Comparisons between arrays were accomplished
through the use of Ingenuity® (Redwood City, CA) path-
way analysis tool bioinformatics software. Discrepancies
between fold-changes of non-statistically significant and
significantly regulated genes within the additional files are
the result of multiple probes for certain genes.
CEM signature
A list of genes regulated by GCs was generated by compar-
ing transcripts regulated in common without regard to sta-
tistical significance among all tested GC-sensitive
conditions in CEM cells: Dex-treated CEM-C7–14, CVZ-
treated CEM-C7–14, Dex-treated CEM-C1–6, CVZ-treated
CEM-C1–15, and Dex plus FSK treated CEM-C1–15 cells
(Fig. 2A). This list was then compared to Dex-treated
resistant CEM-C1–15 and genes failing our "present" call
were designated with an asterisk. The list was further com-
pared to Dex-treated mouse thymocytes and genes failing
our "present" call were assigned an asterisk; genes oppo-
sitely regulated between species (e.g. up-regulated in one
cell type and down-regulated in another) were assigned a
closed circle. Each regulated gene was then analyzed for
statistically significant regulation and marked with bold
type in the table if the condition was met. An intercon-
nected cell signaling network was generated using Ingenu-
ity® for the GC-regulated CEM signatory genes.
Multiple leukemias signature
A list of regulated genes was generated by comparing tran-
scripts regulated in common in the same sense (up or
down) without regard to statistical significance among all
naturally GC-sensitive leukemic cell lines: Dex-treated
CEM-C7–14, CVZ-treated CEM-C7–14, Dex-treated CEM-
C1–6, Dex-treated RS4;11, Dex-treated SUP-B15, and
Dex-treated Kasumi-1 cells (Fig. 2B). Dex-treated resistant
CEM-C1–15 and Dex-treated sensitive mouse thymocytes
were then compared to the multiple leukemia signatory
list and genes called "absent" designated with an asterisk
or oppositely regulated between species designated with a
closed circle. Genes that were regulated statistically signif-
icantly were designated with bold type in the table.
Composite signature
A list of gene transcripts regulated in common by GCs in
all sensitive and resistant- restored-to-sensitive conditions
without regard to statistical significance was generated:
Dex-treated CEM-C7–14, CVZ-treated CEM-C7–14, Dex-
treated CEM-C1–6, Dex-treated RS4;11, Dex-treated SUP-
B15, Dex-treated Kasumi-1, CVZ-treated CEM-C1–15, and
Dex plus FSK treated CEM-C1–15 (Fig. 2C). This list was
then compared to the Dex-resistant CEM-C1–15 and Dex-
sensitive mouse thymocyte conditions. As before,
"absent" calls were assigned an asterisk or oppositely reg-
ulated between species designated with a closed circle.
Present genes regulated to a statistically significant extent
were designated with bold type.
Quantitative real-time PCR
CEM-C7–14 and OPM-2 cells were treated with 10-6 M
Dex and SUP-B15 cells with 10-7 M Dex for 24 hours. RNA
extraction and qRT-PCR was carried out as previously
described [7]. Primers sequences for BCL2L11 (Bim) wereCancer Cell International 2007, 7:18 http://www.cancerci.com/content/7/1/18
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forward: 5' – GTTCTGAGTGTGACCGAGAAGGTA and
reverse: 3' – GTGGCTCTGTCTGTAGGGAGGTA. Primer
sequences for ODC1 were forward: 5' – GACTTTTGAT-
AGTGAAGTTGAGTTGATGA and reverse: 3' – GGCAC-
CGAATTTCACACTGA.
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Additional material
Additional file 1
Gene expression signature for GC-sensitivity in CEM cells. Regulated 
transcripts from vehicle or GC-treated samples were evaluated and com-
pared using Spotfire® and Ingenuity® bioinformatics software. Selection 
criteria for each gene were as follows: probe called present (Methods) on 
the microarray and regulated ≥ 1.2-fold (net 20% change). GC-mediated 
transcripts regulated in common in the same direction among sensitive 
CEM-C7–14 Dex (C7–14 Dx) and CVZ (C7–14 Z), CEM-C1–6 
(C1–6 Dx), CEM-C1–15 CVZ (C1–15 Z), and CEM-C1–15 Dex plus 
FSK (C1–15 Dx+F) cells were obtained. The resulting 96 regulated genes 
are depicted. This list was subsequently compared to Dex-treated resistant 
CEM-C1–15 cells (C1–15 Dx) and to mouse thymocytes (C57/BL6 Dx). 
Genes linked via an Ingenuity® generated signaling pathway (Network) 
are designated with (symbol, closed diamond). Opposite sense regulation 
(Opp. R) between human and mouse is indicated by (symbol, closed cir-
cle). Bold type indicates statistically significant regulation p ≤ 0.05 
between means of vehicle vs. GC-treated. Symbol, asterisk = gene "absent" 
by selection criteria.
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2867-7-18-S1.pdf]
Additional file 2
Gene expression signature for GC-sensitivity in multiple sub-types of sen-
sitive human leukemias. Messenger RNA was extracted and regulated 
genes were analyzed as previously stated. A list of GC-mediated transcripts 
regulated in common in the same sense among sensitive CEM-C7–14 Dex 
(C7–14 Dx) and CVZ (C7–14 Z), CEM-C1–6 (C1–6 Dx), RS4;11 
(RS4 Dx), SUP-B15 (SUP Dx), and Kasumi-1 (Kas Dx) leukemic cells 
was generated. These comparisons resulted in 122 regulated genes. This 
list was subsequently compared to Dex-treated resistant CEM-C1–15 cells 
(C1–15 Dx) and to mouse thymocytes (C57/BL6 Dx). Opposite sense 
regulation (Opp. R) between human and mouse is indicated by (symbol, 
closed circle). Bold type indicates statistically significant regulation p ≤ 
0.05 between means of vehicle vs. GC-treated. Symbol, asterisk = gene 
"absent" by selection criteria.
Click here for file
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2867-7-18-S2.pdf]
Additional file 3
Genes regulated by GCs in sensitive and Dex-resistant-restored-to-sensi-
tive human leukemias. To obtain the final list of genes regulated by GCs 
in all sensitive model systems, the results from Additional file 1 and Addi-
tional file 2 were combined. Depicted are 191 genes, (83 induced, symbol 
plus) and (108 repressed, symbol minus) genes specific to and regulated 
in common between the CEM and other leukemia signatures.
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Additional file 4
Genes present on both HG_U95 Av2 and HGU133 Plus 2.0 chips. Genes 
regulated by GCs using selection criteria (Methods) in CEM-C7–14, 
CEM-C1–6, RS4;11, SUP-B15, and Kasumi-1 cells. Bold type indicates 
statistically significant regulation p ≤ 0.05 between means of vehicle vs. 
GC-treated. Blank = gene "absent" by selection criteria.
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[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-18-S4.pdf]
Additional file 5
Adult ALL vs. Pediatric ALL and AML. Genes statistically significantly 
regulated by Dex in adult B-cell ALL RS4;11 cells compared to other GC-
sensitive pediatric leukemias. Blank = gene "absent" by selection criteria.
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Additional file 6
Myeloid AML vs. Lymphoid ALL. Genes statistically significantly regu-
lated by Dex in Kasumi-1 AML cells compared to GC-sensitive lymphoid 
leukemic cells. Blank = gene "absent" by selection criteria.
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